Adma Biologics (ADMA) Asset Utilization Ratio (2012 - 2026)
Adma Biologics' (ADMA) quarterly Asset Utilization Ratio came in at 0.86 in Q4 2025, down 11.82% YoY from 0.97 in Q4 2024, and down 1.34% on a QoQ basis from 0.87 in Q3 2025.
Adma Biologics (ADMA) Asset Utilization Ratio (2012 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 12 years of Asset Utilization Ratio data on file, last reported at 0.86 in Q4 2025.
- Quarterly Asset Utilization Ratio fell 11.82% year-over-year to 0.86 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.86 (down 11.82% YoY) and the FY2025 annual result came in at 0.92, down 12.09% from the prior year.
- Asset Utilization Ratio fell to 0.86 in Q4 2025, from 0.87 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.03 in Q2 2024 to a low of 0.22 in Q1 2021.
- A 5-year average of 0.69 and a median of 0.74 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2021 — Asset Utilization Ratio sank 32.25% — and 2022, when it soared 139.58%.
- Tracing ADMA's Asset Utilization Ratio over 5 years: stood at 0.43 in 2021, then jumped by 41.33% to 0.6 in 2022, then jumped by 47.56% to 0.89 in 2023, then grew by 9.29% to 0.97 in 2024, then slipped by 11.82% to 0.86 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.86 (Q4 2025), 0.87 (Q3 2025), and 0.89 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.79 |
| Dec 31, 2025 | 0.86 |
| Sep 30, 2025 | 0.87 |
| Jun 30, 2025 | 0.89 |
| Mar 31, 2025 | 0.92 |
| Dec 31, 2024 | 0.97 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | 1.03 |
| Mar 31, 2024 | 0.96 |
| Dec 31, 2023 | 0.89 |
| Sep 30, 2023 | 0.80 |
| Jun 30, 2023 | 0.61 |
| Mar 31, 2023 | 0.65 |
| Dec 31, 2022 | 0.60 |
| Sep 30, 2022 | 0.67 |
| Jun 30, 2022 | 0.59 |
| Mar 31, 2022 | 0.42 |
| Dec 31, 2021 | 0.43 |
| Sep 30, 2021 | 0.29 |
| Jun 30, 2021 | 0.25 |